INDSWFTLAB
Ind-Swift Laboratories Limited
NSELast Traded Price
₹361
-0.05 (-0.01%)
Open
₹363.5
High
₹367.25
Low
₹345
Prev Close
₹361.05
Industry
Pharmaceuticals
Market Cap
3142.36 Cr
Filing History
Recent corporate announcements and filings for INDSWFTLAB
Ownership
Positive
2026-10-12 17:39
Essix Biosciences Limited (promoter group) acquired 14,00,000 equity shares of Ind-Swift Laboratories Limited on October 8, 2026.
- Acquisition was done via conversion of fully convertible warrants into equity shares.
- Post-acquisition, Essix Biosciences' shareholding in the target company increased from 37.81% (3,28,82,521 shares) to 38.80% (3,42,82,521 shares).
Ownership
Positive
2026-10-08 18:45
- Ind-Swift Laboratories approved the allotment of 14,00,000 equity shares of face value ₹10 each upon conversion of fully convertible warrants.
- The conversion was made to Essix Biosciences Limited (promoter group) upon receiving the balance 75% consideration of ₹147 per warrant, aggregating to ₹20,58,00,000.
- Post-allotment, the paid-up equity share capital increased from ₹86.71 crore to ₹86.96 crore.
Routine
Neutral
2026-09-28 19:09
- Ind-Swift Laboratories Ltd has issued a reminder letter to physical security holders for mandatory furnishing of PAN, KYC, and nomination details pursuant to SEBI Master Circular dated May 07, 2024.
- Shareholders must submit required forms (ISR-1, ISR-2, SH-13, etc.) to the company's RTA, Alankit Limited.
- Failure to update details restricts shareholders from lodging grievances or receiving payments like dividends through electronic mode.
Routine
Neutral
2026-09-28 19:03
- Trading window closure for all designated persons, promoters, and insiders w.e.f. October 1, 2026.
- Closure remains effective until 48 hours after the declaration of Q2/H1 FY26 financial results.
Business Update
Neutral
2026-09-23 17:16
- Concall Schedule
- Concall Date: 29th September, 2026
- Concall Time: 01:00 P.M. (IST)
- Meeting with Arihant Capital (Group Meeting, Virtual Mode).
Ownership
Positive
2026-09-21 18:12
- Ind-Swift Laboratories Limited's promoter group, Essix Biosciences Limited and PACs, acquired 70,00,000 fully convertible warrants on September 17, 2026, via preferential issue. These warrants are convertible into equity shares of face value ₹10 each, representing 7.45% of the total diluted share/voting capital.
Ownership
Positive
2026-09-17 17:46
- Allotment of 7,000,000 Fully Convertible Warrants to Essix Biosciences Limited (Promoter & Promoter Group).
- Issue price: ₹196 per warrant.
- Aggregate warrant subscription price: ₹34,30,00,000.